A number of diseases tend to peak in the winter, thanks to indoor gatherings that help germs spread. The list includes not ...

Researchers evaluated the real-world effectiveness of nirsevimab in preventing ICU admission and acute respiratory failure associated with RSV among infants.

GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) ...

GSK (GSK) stock is in focus as an expert panel of the European Medicines Agency ((EMA)) endorses the company's Arexvy RSV ...

The vaccines were found to decrease the risk of needing medical care in the first six months after vaccination by 76 percent ...

A new study has found that a significant percentage of adults in the United States have at least one risk factor for severe respiratory syncytial virus (RSV), even as eligibility for the RSV ...

Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...

The FDA is reviewing the safety of two drugs, Clesrovimab and Nirsevimab, which are approved for the prevention of RSV in infants and toddlers, and are 80-90% effective at reducing the risk of ...

FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...